Eli Lilly's Zepbound Demonstrates Potential as Sleep Apnea Treatment
Wednesday, 17 April 2024, 13:44
Eli Lilly's Zepbound Shows Promise for Sleep Apnea
The pharmaceutical giant Eli Lilly has reported positive outcomes in late-stage trials of its weight loss drug Zepbound, hinting at its potential as a treatment for sleep apnea.
Major Milestone Towards FDA Approval
The company plans to present the trial data at an upcoming medical conference and submit it to the U.S. Food and Drug Administration by mid-year, a crucial move in the path to regulatory approval.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.